Addressing the roadblocks to rapid AST as the clinical standard

Rapid antimicrobial susceptibility testing (AST) is a cornerstone in the global effort to combat antimicrobial resistance (AMR) and improve patient outcomes. While ultra-rapid technologies are redefining clinical microbiology, widespread adoption remains a complex challenge for many healthcare facilities. Understanding the intersection of technological innovation, clinical evidence, and laboratory logistics is essential for a successful transition to faster diagnostics.

This SelectScience resource, produced in partnership with Gradientech, developers of the QuickEST™ ultra-rapid AST system, presents the findings of a comprehensive industry-wide survey. The results highlight the current state of AST implementation, identifying the critical roadblocks labs face—from workflow integration to cost-benefit analysis—and providing a clear roadmap for moving toward a faster, more precise diagnostic standard.

Key takeaways from the report:

• Why most clinical microbiology labs are now actively prioritizing and evaluating new diagnostic tools.
• How ultra-rapid AST delivers measurable improvements in time-to-result (TTR) and targeted therapy.
• Identifying the support labs need from manufacturers to bridge the gap between pilot programs and routine clinical use.
• Expert analysis on overcoming common hurdles in cost, staff training, and evidence-based integration.
• Exploring the demand for precise, high-throughput technologies that fit modern lab environments.

Whether you are currently evaluating rapid AST platforms or building a business case for future investment, this infographic breaks down the data you need to drive successful clinical adoption.

Download now to discover how your lab can overcome diagnostic roadblocks and set a new standard in AST.